Big Money Are Selling Macrogenics Inc (NASDAQ:MGNX), Sentiment at 1.11

Macrogenics Inc’s Sentiment

In Q3 2018 Macrogenics Inc (NASDAQ:MGNX) big money sentiment decreased to 1.11, according to filings. So its down -0.37, from 2018Q2’s 1.48. 51 investment managers opened new or increased holdings, while 46 cut down and sold positions in Macrogenics Inc so the sentiment turned negative. Funds own 33.26 million shares, down from 34.48 million shares in 2018Q2. Funds holding Macrogenics Inc in top 10 was flat from 1 to 1 for the same number . 8 Investors Sold All; 38 Reduced Holdings; 33 increased holdings while 18 investment managers bought holdings.

Significant Macrogenics Inc Investors

Ecor1 Capital Llc owns 1.48 million shares in Macrogenics Inc as of Q3 2018. As of Q3 2018, 2.99 million shares of Macrogenics Inc are owned by Bb Biotech Ag. Moreover, Rhenman & Partners Asset Management Ab reported 341,586 shares in Macrogenics Inc equivalent to 0.73% of its long stock exposure. The California-based fund Dafna Capital Management Llc have invested about 0.69% of the active investment manager’s stock portfolio in Macrogenics Inc. The Oregon-based fund Hood River Capital Management Llc looks positive on Macrogenics Inc, owning 668,640 shares.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States.The firm is valued at $899.70 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.Last it reported negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

Ticker’s shares touched $21.29 during the last trading session after 1.43% change.MacroGenics, Inc. is downtrending after having declined 29.46% since February 14, 2018. MGNX has 5.66 million volume or 424.34% up from normal. The stock underperformed the S&P500 by 29.46%.

MacroGenics, Inc. (NASDAQ:MGNX)’s earnings report is awaited on February, 26., according to Faxor. Analysts predict $-1.04 earnings per share. That’s $3.84 down or 137.14 % from 2018’s earnings of $2.8. Analysts at Wall Street see MacroGenics, Inc.’s 28.40 % negative EPS growth compared to $-0.81 earnings per share for previous quarter.

Point72 Asset Mgmt L P, Connecticut-based fund reported 1.13M shs. Ameriprise Finance invested in 0% or 551,149 shs. Alliancebernstein Limited Partnership has invested 0% of its capital in MacroGenics, Inc. (NASDAQ:MGNX). Victory Mngmt stated it has 105,770 shs or 0% of all its holdings. Arrowstreet Capital Ltd Partnership owns 23,663 shs for 0% of their capital. Meeder Asset Management accumulated 243 shs or 0% of the stock. Moreover, Price T Rowe Assocs Incorporated Md has 0.01% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 2.28M shs. Daiwa Secs Grp Inc owns 203 shs for 0% of their capital. Schwab Charles Investment Management owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 246,885 shs. The Illinois-based Northern Corporation has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Los Angeles Capital Mngmt Equity Rech holds 0.01% of its capital in MacroGenics, Inc. (NASDAQ:MGNX) for 75,850 shs. 34,715 are held by Rhumbline Advisers. Pnc Financial Group Inc Inc owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 27 shs. Macquarie Gp Ltd has 80,000 shs. Endurant Cap Mngmt Limited Partnership holds 0.38% in MacroGenics, Inc. (NASDAQ:MGNX) or 39,456 shs.

MacroGenics, Inc. registered $258,567 net activity with 0 insider buys and 3 insider sales since February 6, 2019. On Wednesday, February 6 Fust Matthew K sold $203,427 worth of MacroGenics, Inc. (NASDAQ:MGNX) or 6,924 shs. Peters Jeffrey Stuart sold $2,040 worth of MacroGenics, Inc. (NASDAQ:MGNX) or 68 shs on Wednesday, February 6.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

In total 4 analysts cover Macrogenics (NASDAQ:MGNX). “Buy” rating has 1, “Sell” are 1, while 2 are “Hold”. 25% are bullish. 4 are the (NASDAQ:MGNX)’s analyst reports since September 10, 2018 according to StockzIntelligence Inc. On Thursday, February 7 the stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Market Perform” rating given by Raymond James. On Monday, February 4 the stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Sell” rating given by Citigroup. On Monday, September 10 the firm has “Buy” rating by BTIG Research given. On Thursday, February 7 Wedbush downgraded the shares of MGNX in report to “Neutral” rating.

For more MacroGenics, Inc. (NASDAQ:MGNX) news released recently go to:,,, or The titles are as follows: “MacroGenics to Present at the 37th Annual J.P. Morgan Healthcare Conference – GlobeNewswire” released on January 07, 2019, “MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA – GlobeNewswire” on January 25, 2019, “Pre-Open Stock Movers 02/06: (MGNX) (SNAP) (ZEN) Higher; (ARLO) (EA) (MTSI) Lower (more…) –” with a publish date: February 06, 2019, “MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab – GlobeNewswire” and the last “Pre-Open Stock Movers 02/13: (DBD) (LSCC) (GERN) Higher; (AQ) (BABY) (QLYS) Lower (more…) –” with publication date: February 13, 2019.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.